ALKS 2680 showed a clear dose-response relationship in improving wakefulness in NT2 and IH patients. Can you elaborate on the significance of these findings and how they compare to the current standard of care for these conditions?

Given the general tolerability of ALKS 2680 across all doses tested, could you discuss the importance of this safety profile for long-term management of NT2 and IH, especially considering the chronic nature of these conditions?

ALKS 2680, as an orexin 2 receptor agonist, represents a novel approach to treating sleep disorders. How does this mechanism of action potentially offer advantages over current treatments that primarily focus on symptom management?

Improved wakefulness directly influences quality of life and daily functioning for patients with NT2 and IH. Based on the study's outcomes, what potential impacts do you foresee ALKS 2680 having on patients' daily lives and overall well-being?

The study noted mild to moderate TEAEs, with pollakiuria, insomnia, and dizziness being more common. How should clinicians weigh these effects when considering ALKS 2680 for their patients, and what monitoring strategies would you recommend?

With Phase 2 studies planned, what are the critical areas of focus that researchers should consider to further validate the efficacy and safety of ALKS 2680? Are there specific patient populations or subgroups within NT2 and IH that might benefit more distinctly from this treatment?

How does ALKS 2680 compare with other orexin agonists in development or on the market in terms of efficacy, safety, and potential advantages for patients with sleep disorders?

Looking beyond the clinical aspects, what are the potential implications of ALKS 2680's successful development for the broader healthcare system, including aspects of patient access, healthcare costs, and the overall landscape of sleep disorder treatments?